Acute Lymphoblastic Leukemia, in Relapse research hub
3 indexed studies · 3 currently recruiting
- recruitingPHASE1, PHASE2
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
This study looks at new drug combinations for children and young adults with blood cancers (leukaemia and lymphoma) that have come back or not responded to treatment. It focuses on cancers with specific genetic changes, hoping to find safer and more effective ways to help them.
Austria · Belgium · Denmark - recruitingPHASE1, PHASE2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study looks at new treatments for children and young adults with specific types of blood cancer that have come back or not responded to previous treatment. It tests a combination of medicines to see if they are safe and work well for those whose cancer has certain genetic changes.
Austria · Belgium · Denmark - recruitingPHASE1, PHASE2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study is for children and young adults aged 1-21 with specific types of aggressive blood cancers that have come back or not responded to treatment. It tests new drug combinations to see if they're safe and work well for those with certain genetic changes in their cancer.
Austria · Belgium · Denmark